Advanced

May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol

Serra, Massimo; Pasello, Michela; Manara, Maria Cristina; Scotlandi, Katia; Ferrari, Stefano; Bertoni, Franco; Mercuri, Mario; Alvegård, Thor LU ; Picci, Piero and Bacc, Gaetano, et al. (2006) In International Journal of Oncology 29(6). p.1459-1468
Abstract
The aim was to evaluate the clinical impact of P-glycoprotein in primary non-metastatic high-grade osteosarcoma patients, treated with neoadjuvant chemotherapy protocols. P-glycoprotein was assessed by immunohistochemistry on paraffin-embedded tissue samples collected at time of diagnosis from 94 osteosarcoma patients, treated with the Italian Sarcoma Group/Scandinavian Sarcoma Group 1 (ISG/SSG 1) protocol. P-glycoprotein-positivity at diagnosis was found in 53/94 ISG/SSG 1 cases (56%) and emerged as the single factor significantly associated with an unfavourable outcome from survival and multivariate analyses. A comparative analysis of the subgroup of 94 patients considered for P-glycoprotein evaluation and the whole series of ISG/SSG 1... (More)
The aim was to evaluate the clinical impact of P-glycoprotein in primary non-metastatic high-grade osteosarcoma patients, treated with neoadjuvant chemotherapy protocols. P-glycoprotein was assessed by immunohistochemistry on paraffin-embedded tissue samples collected at time of diagnosis from 94 osteosarcoma patients, treated with the Italian Sarcoma Group/Scandinavian Sarcoma Group 1 (ISG/SSG 1) protocol. P-glycoprotein-positivity at diagnosis was found in 53/94 ISG/SSG 1 cases (56%) and emerged as the single factor significantly associated with an unfavourable outcome from survival and multivariate analyses. A comparative analysis of the subgroup of 94 patients considered for P-glycoprotein evaluation and the whole series of ISG/SSG 1 patients showed that this marker retained its prognostic value also in the latter group. In osteosarcoma patients treated with doxorubicin-based chemotherapy protocols, P-glycoprotein overexpression at diagnosis is an important adverse prognostic factor for outcome. P-glycoprotein evaluation can therefore constitute the basis for stratifying, at diagnosis, osteosarcoma patients for whom alternative treatments may be considered. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prognosis, chemotherapy, drug resistance, osteosarcoma, P-glycoprotein
in
International Journal of Oncology
volume
29
issue
6
pages
1459 - 1468
publisher
D.A. Spandidos
external identifiers
  • wos:000242312100015
  • scopus:36049026825
ISSN
1019-6439
language
English
LU publication?
yes
id
90553c68-7e0f-4357-a473-5f2eacab6e5c (old id 685488)
date added to LUP
2008-01-03 15:50:04
date last changed
2019-10-15 04:59:08
@article{90553c68-7e0f-4357-a473-5f2eacab6e5c,
  abstract     = {The aim was to evaluate the clinical impact of P-glycoprotein in primary non-metastatic high-grade osteosarcoma patients, treated with neoadjuvant chemotherapy protocols. P-glycoprotein was assessed by immunohistochemistry on paraffin-embedded tissue samples collected at time of diagnosis from 94 osteosarcoma patients, treated with the Italian Sarcoma Group/Scandinavian Sarcoma Group 1 (ISG/SSG 1) protocol. P-glycoprotein-positivity at diagnosis was found in 53/94 ISG/SSG 1 cases (56%) and emerged as the single factor significantly associated with an unfavourable outcome from survival and multivariate analyses. A comparative analysis of the subgroup of 94 patients considered for P-glycoprotein evaluation and the whole series of ISG/SSG 1 patients showed that this marker retained its prognostic value also in the latter group. In osteosarcoma patients treated with doxorubicin-based chemotherapy protocols, P-glycoprotein overexpression at diagnosis is an important adverse prognostic factor for outcome. P-glycoprotein evaluation can therefore constitute the basis for stratifying, at diagnosis, osteosarcoma patients for whom alternative treatments may be considered.},
  author       = {Serra, Massimo and Pasello, Michela and Manara, Maria Cristina and Scotlandi, Katia and Ferrari, Stefano and Bertoni, Franco and Mercuri, Mario and Alvegård, Thor and Picci, Piero and Bacc, Gaetano and Smeland, Sigbjorn},
  issn         = {1019-6439},
  keyword      = {prognosis,chemotherapy,drug resistance,osteosarcoma,P-glycoprotein},
  language     = {eng},
  number       = {6},
  pages        = {1459--1468},
  publisher    = {D.A. Spandidos},
  series       = {International Journal of Oncology},
  title        = {May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol},
  volume       = {29},
  year         = {2006},
}